Status:
COMPLETED
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Lead Sponsor:
Tarsus Pharmaceuticals, Inc.
Conditions:
Demodex Blepharitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Detailed Description
This Phase 4 study is a prospective, multicenter, randomized, vehicle-controlled, double-masked, two-arm, parallel treatment clinical trial of participants who have Demodex blepharitis and are current...
Eligibility Criteria
Inclusion
- Be willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol
- Must meet the following criteria in at least one eye: Have more than 10 eyelashes (Grade 2 or higher) with collarettes on the upper or lower eyelid; have at least Grade 1 erythema of the lower eyelid; and have a total meibomian gland secretion score ≥ 12 but ≤ 32 AND have a minimum of 6 expressible glands for the 15 glands evaluated on the lower eyelid
- Currently wearing soft contact lenses on both eyes an average of at least 2 days per week with an average minimum wearing time of 6 hours each day over the past 3 months and is able and willing to continue to wear contact lenses during the study
Exclusion
- Use of artificial tears or rewetting drops within 24 hours of the Screening visit or unwilling to forego the use of this treatment during the study
- Prescription AND systemic, drug delivery implant, ocular topical, or topical: antibacterial, anti-parasitic, or anti-inflammatory corticosteroid treatment within 14 days of the Screening or Day 1 visits
- Use of TYRVAYA™ Nasal Spray (varenicline solution, Oyster Point Pharma) within 14 days of the Screening visit or unwilling to forego the use of this treatment during the study
- Use of XDEMVY™ (lotilaner ophthalmic solution) 0.25%, Tarsus Pharmaceuticals, Inc., within 12 months of the Screening visit
- Treatment for blepharitis (e.g., tea tree oil-based products, hypochlorous acid-based products, commercial eyelid foams, eyelid wipes, lid scrubs, etc.) within 14 days of the Screening visit or unwilling to forego the use of these treatments during the study
- Use of artificial eyelashes or eyelash extensions at the Screening visit if they limit accurate eyelid margin assessment
- Currently pregnant or lactating
Key Trial Info
Start Date :
December 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2025
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT06182358
Start Date
December 27 2023
End Date
January 27 2025
Last Update
July 2 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Site
Cave Creek, Arizona, United States, 85331
2
Site
Long Beach, California, United States, 90805
3
Vision Institute
Colorado Springs, Colorado, United States, 80907
4
Site
Delray Beach, Florida, United States, 33484